Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ME/CFS according to Canadian criteria (2003)~* Duration of ME/CFS at least 2 years~* Mild/Moderate, Moderate, Moderate/Severe and Severe ME/CFS may be included~* Age 18-65 years~* Signed informed consent~Exclusion Criteria:~* Patients with fatigue who do not comply by the diagnostic Canadian criteria (2003) for ME/CFS~* Duration of ME/CFS less than 2 years~* Mild ME/CFS~* Very severe ME/CFS (bedridden requiring help for all tasks)~* Patients where the workup uncovers other pathology as possible cause of symptoms~* Pregnancy or breast feeding~* Previous malignant disease (except basal cell carcinoma of skin and cervical carcinoma in situ/dysplasia)~* Previous long-term systemic treatment with immunosuppressive agents (e.g. azathioprine, ciclosporin, mycophenolate mofetil). Except steroid treatment for e.g. obstructive lung disease or autoimmune diseases such as e.g. ulcerative colitis~* Serious endogenous depression~* Lack of ability to complete the study including follow-up~* Reduced renal function (creatinine \> 1.5 x UNL)~* Reduced liver function (bilirubin or transaminases \> 1.5 x UNL)~* Known hypersensitivity to cyclophosphamide or metabolites~* Reduced bone marrow function~* Ongoing cystitis or urinary tract obstruction~* Known HIV positivity, previous hepatitis B or hepatitis C, or reason to suspect other ongoing and clinically relevant infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).